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Brucellosis 
Reactivation after 
28 Years
To the Editor: Approximately 
10% of patients with brucellosis expe-
rience a relapse, 90% of which occur 
within a year after discontinuation of 
antimicrobial drug therapy (1,2). Here 
we report a patient who had brucel-
losis in a disease-endemic area, im-
migrated to a brucellosis-free region, 
and experienced focal reactivation in 
her gallbladder 28 years later. To our 
knowledge, this interval is among the 
longest reported asymptomatic inter-
vals between a fi rst brucellosis episode 
and reactivation. The case suggests 
that physicians should not disregard 
remote histories of brucellosis and 
past residence in brucellosis-endemic 
areas when confronted with possible 
reactivation disease.
A woman, born in 1955, had pro-
longed fever without focal symptoms 
in 1981 and had received a diagnosis of 
brucellosis while living near Valencia, 
Spain. The brucellosis was attributed 
to an episode of eating unpasteurized 
cheese from the local dairy and was 
successfully treated. She immigrated 
to Switzerland in 1990 and was well 
until March 2009, when malaise and 
right upper quadrant pain developed, 
without fever. She was otherwise 
healthy and did not take any medi-
cation. Computed tomography (CT) 
scan showed a mass contiguous with 
the gallbladder, extending intrahe-
patically, with concentric calcifi ca-
tions and multiple gallstones (Figure). 
Gallbladder cancer was suspected, but 
when a laparotomy was performed, 
an acutely infl amed gallbladder with 
a surrounding infl ammatory mass was 
found and excised. Gallbladder cul-
tures on standard media (Columbia 
agar with 5% sheep’s blood, chocolate 
agar, Brucella blood agar, and brain-
heart infusion broth) were discarded 
when they remained sterile after 5 
days of incubation. Histopathologic 
examination showed granulomatous 
cholecystitis, and the patient was re-
ferred for infectious disease consulta-
tion. Formalin-fi xed gallbladder tis-
sue was negative for Mycobacterium 
tuberculosis complex DNA but posi-
tive for Brucella melitensis by PCR 
(3). Blood cultures (BACTEC Plus 
Aerobic/F and Anaerobic/F [Becton 
Dickinson, Allschwil, Switzerland], 
incubated for 10 days) remained ster-
ile. No Brucella DNA was detected 
in blood and serum (1,2), and a rose 
bengal serum agglutination test was 
negative for anti-Brucella antibodies. 
Because of the rarity of the manifes-
tation (late reactivation) and location 
(gallbladder), plus a residual abscess 
shown on CT scan 8 weeks after sur-
gery, prolonged treatment with doxy-
cycline and rifampin was adminis-
tered for 3 months, with gentamicin 
added during the initial 2 weeks (4). 
Nine months after antimicrobial drug 
therapy was discontinued, the patient 
remains well.
Switzerland reported the elimina-
tion of animal brucellosis in 1963 (5) 
and has offi cially been brucellosis-free 
since 1998, according to article 14.1.2. 
of the Terrestrial Animal Health Code 
(www.oie.int/eng/normes/mcode/
en_chapitre_1.14.1.htm). The last 
case of B. melitensis infection in a 
sheep or goat in Switzerland was re-
ported in 1985. The annual number of 
human brucellosis cases reported in 
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Figure. A) Contrast-enhanced computerized tomography (CT) scan showing a calcifi ed 
gallbladder wall (arrow), a surrounding, calcifi ed mass located peripherally in the liver, 
and an abscess in the adjacent fat tissue (arrowhead). B) T2-weighted axial magnetic 
resonance imaging shows multiple gallstones and a thickened gallbladder wall (arrow), 
infl ammation and edema of the adjacent liver, fat tissue, and proximal duodenum. C) Eight 
weeks after cholecystectomy, contrast-enhanced CT shows a residual abscess in the 
adjacent fat tissue (arrowhead). D) Contrast-enhanced CT 5 months after cholecystectomy 
shows only minimal changes in the gallbladder bed and surrounding tissues, and no 
residual abscess.
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Switzerland remains low but seems to 
be increasing; 3, 5, and 13 cases were 
recorded in 2007, 2008, and 2009, re-
spectively (6). 
Most of these cases were linked 
to international travel or ingestion of 
food products imported from disease-
endemic areas, e.g., Turkey. Our pa-
tient traveled annually to her family’s 
home town in Spain, but she vigor-
ously denied exposure to any dairy or 
meat products imported from an area 
with known brucellosis endemicity 
or to any unpasteurized dairy prod-
ucts in general since she left Spain 
in 1990. Therefore, the most likely 
explanation was brucellosis reactiva-
tion, 28 years after the initial episode 
in Spain, where brucellosis was en-
demic. In the absence of a positive 
culture, brucellosis remains formally 
unproven. However, the granuloma-
tous infl ammation in the resected 
gallbladder tissue, the absence of 
another identifi ed cause (e.g., tuber-
culosis), and the patient’s clinical 
and radiologic response to specifi c 
anti-Brucella treatment argue against 
the positive PCR result being merely 
attributable to long-term, persistent, 
but clinically latent, brucellosis.
Ariza (7) and Diaz (8) have report-
ed patients with chronic hepatosplenic 
brucellosis after remote episodes of 
brucellosis (2–40 years previously). 
Because these patients lived in dis-
ease-endemic areas, reinfection can-
not be excluded. Brucella organisms 
persist intracellularly, and their DNA 
has been detected in the peripheral 
blood of asymptomatic patients, even 
years after the diagnosis of clinical 
brucellosis and its clinically success-
ful cure. These facts suggest that the 
outcome of treated brucellosis may be 
a chronic, persistent, asymptomatic
infection, rather than complete bacte-
rial eradication (9).
The pathogenesis of unusually 
late brucellosis reactivation in our pa-
tient remains obscure. Reactivation has 
only rarely been linked to underlying 
illnesses or immunosuppression (2). 
Rare cases of reactivation have been 
reported during pregnancy. Brucella 
persistence has been recorded inside 
calcifi ed lesions in chronic hepatos-
plenic brucellosis (7), and adherence 
to foreign bodies such as joint prosthe-
ses or prosthetic heart valves and other 
cardiac devices may occur, perhaps in 
association with episodes of transient 
Brucella bacteremia (10). Unlike the 
situation with typhoid fever, no evi-
dence links the presence of gallstones 
to the persistence of Brucella organ-
isms in humans.
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